3-(3-Pyridylmethylidene)-2-indolinone reduces the severity of colonic injury in a murine model of experimental colitis

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Wang, Kun Ping ^a   Zhang, Chao ^a   Zhang, Shou Guo ^a   Liu, En Dong ^b   Dong, Lan ^c   Kong, Xiang Zhen ^d   Cao, Peng ^e   Hu, Chun Ping ^e   Zhao, Ke ^a   Zhan, Yi Qun ^a   Dong, Xiao Ming ^d   Ge, Chang Hui ^a   Yu, Miao ^a   Chen, Hui ^a   Wang, Lin ^a   Yang, Xiao Ming ^a,d   Li, Chang Yan ^a,b  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^d TIANJIN UNIVERSITY   (China)

^e Jiangsu Province Institute of Traditional Chinese Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; CHEMICAL ACTIVATION; CHEMICAL COMPOUNDS; DISEASE CONTROL; GENE EXPRESSION; MAMMALS; TRANSCRIPTION;

ACTIVITY INDEX; ANTI-INFLAMMATORIES; ANTI-INFLAMMATORY RESPONSE; ANTI-OXIDANT RESPONSE; BODY WEIGHT LOSS; EXPRESSION LEVELS; HISTOPATHOLOGICAL ANALYSIS; SYNTHESIZED DERIVATIVES;

DISEASES;

3 (3 PYRIDYLMETHYLIDENE) 2 INDOLINONE; DEXTRAN SULFATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXINDOLE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; 3-(3-PYRIDYLMETHYLIDENE)-2-INDOLINONE; ANTIINFLAMMATORY AGENT; CYTOKINE; HEME OXYGENASE 1; INDOLE DERIVATIVE; NQO1 PROTEIN, MOUSE; PYRIDINE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; EXPERIMENTAL COLITIS; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; COLITIS; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SYNTHESIS;

ANIMALIA; MURINAE; MUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS; COLON; CYTOKINES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEME OXYGENASE-1; INDOLES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MICE, KNOCKOUT; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; NF-KAPPA B; PYRIDINES; SEVERITY OF ILLNESS INDEX;

EID: 84927153600     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/959253     Document Type: Article

References (31)

1. T. A. Ullman and S. H. Itzkowitz, "Intestinal inflammation and cancer, " Gastroenterology, vol. 140, no. 6, pp. 1807-1816, 2011.
2. Y. J. Kim, E.-H. Kim, and K. B. Hahm, "Oxidative stress in inflammation-based gastrointestinal tract diseases: challenges and opportunities, " Journal of Gastroenterology andHepatology, vol. 27, no. 6, pp. 1004-1010, 2012.
3. A. T. Dinkova-Kostova, W. D. Holtzclaw, R. N. Cole et al., "Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants, " Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 18, pp. 11908-11913, 2002.
4. H. Y. Cho, A. E. Jedlicka, S. P.M. Reddy et al., "Role ofNRF2 in protection against hyperoxic lung injury in mice, "TheAmerican Journal of Respiratory Cell and Molecular Biology, vol. 26, no. 2, pp. 175-182, 2002.
5. H.-Y. Cho, S. P. M. Reddy, M. Yamamoto, and S. R. Kleeberger, "The transcription factor NRF2 protects against pulmonary fibrosis, " The FASEB Journal, vol. 18, no. 11, pp. 1258-1260, 2004.
6. T. Rangasamy, C. Y. Cho, R. K. Thimmulappa et al., "Genetic ablation of Nrf2 enhances susceptibility to cigarette smokeinduced emphysema in mice, "The Journal of Clinical Investigation, vol. 114, no. 9, pp. 1248-1259, 2004.
7. T. Rangasamy, J. Guo, W. A. Mitzner et al., "Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice, " Journal of ExperimentalMedicine, vol. 202, no. 1, pp. 47-59, 2005.
8. R. K. Thimmulappa, H. Lee, T. Rangasamy et al., "Nrf2 is a critical regulator of the innateimmune response and survival during experimental sepsis, " The Journal of Clinical Investigation, vol. 116, no. 4, pp. 984-995, 2006.
9. T.O. Khor, M.-T.Huang, K.H. Kwon, J.Y.Chan, B. S. Reddy, and A.-N. Kong, "Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis, " Cancer Research, vol. 66, no. 24, pp. 11580-11584, 2006.
10. T.O. Khor, M. T. Huang, A. Prawan et al., "Increased susceptibility of Nrf2 knockoutmice to colitis-associated colorectal cancer, " Cancer Prevention Research, vol. 1, no. 3, pp. 187-191, 2008.
11. W. O. Osburn, B. Karim, P. M. Dolan et al., "Increased colonic inflammatory injury and formation of aberrant crypt foci in Nrf2-deficient mice upon dextran sulfate treatment, " International Journal of Cancer, vol. 121, no. 9, pp. 1883-1891, 2007.
12. J.-W. Yao, J. Liu, X.-Z. Kong et al., "Induction of activation of the antioxidant response element and stabilization of Nrf2 by 3-(3-pyridylmethylidene)-2-indolinone (PMID) confers protection against oxidative stress-induced cell death, " Toxicology and Applied Pharmacology, vol. 259, no. 2, pp. 227-235, 2012.
13. M. Murano, K. Maemura, I. Hirata et al., "Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis, " Clinical and Experimental Immunology, vol. 120, no. 1, pp. 51-58, 2000.
14. S.N. S.Murthy, H. S. Cooper, H. Shim, R. S. Shah, S.A. Ibrahim, and D. J. Sedergran, "Treatment of dextran sulfate sodiuminduced murine colitis by intracolonic cyclosporin, " Digestive Diseases and Sciences, vol. 38, no. 9, pp. 1722-1734, 1993.
15. Y. Li and A. K. Jaiswal, "Regulation of human NAD(P)H: quinone oxidoreductase gene. Role of AP1 binding site contained within human antioxidant response element, " The Journal of Biological Chemistry, vol. 267, pp. 15097-15104, 1992.
16. A. L. Theiss, M.Vijay-Kumar, T. S. Obertone et al., "Prohibitin is a novel regulator of antioxidant response that attenuates colonic inflammation in mice, " Gastroenterology, vol. 137, no. 1, pp. 199.e6-208.e6, 2009.
17. R. Boismenu and Y. Chen, "Insights from mouse models of colitis, " Journal of Leukocyte Biology, vol. 67, no. 3, pp. 267-278, 2000.
18. M. C. Jaramillo and D. D. Zhang, "The emerging role of the Nrf2-Keap1 signaling pathway in cancer, " Genes and Development, vol. 27, no. 20, pp. 2179-2191, 2013.
19. K. N. Lewis, J. Mele, J. D. Hayes, and R. Buffenstein, "Nrf2, a guardian of healthspan and gatekeeper of species longevity, " Integrative and Comparative Biology, vol. 50, no. 5, pp. 829-843, 2010.
20. S. P.Guan, W. Tee, D. S. W. Ng et al., "Andrographolide protects against cigarette smoke-induced oxidative lung injury via augmentation of Nrf2 activity, " British Journal of Pharmacology, vol. 168, no. 7, pp. 1707-1718, 2013.
21. K. T. Liby and M. B. Sporn, "Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease, " Pharmacological Reviews, vol. 64, no. 4, pp. 972-1003, 2012.
22. R. K. Thimmulappa, R. J. Fuchs, D. Malhotra et al., "Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils, " Antioxidants and Redox Signaling, vol. 9, no. 11, pp. 1963-1970, 2007.
23. B. Gao, A.Doan, and B. M.Hybertson, "The clinical potential of influencing Nrf2 signaling in degenerative and immunological disorders, " Clinical Pharmacology: Advances and Applications, vol. 6, no. 1, pp. 19-34, 2014.
24. G.-H. Liu, J. Qu, and X. Shen, "NF-κB/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment ofHDAC3 toMafK, " Biochimica et Biophysica Acta, vol. 1783, no. 5, pp. 713-727, 2008.
25. W. Jin, L. Zhu, Q. Guan et al., "Influence of Nrf2 genotype on pulmonary NF-κB activity and inflammatory response after traumatic brain injury, " Annals of Clinical and Laboratory Science, vol. 38, no. 3, pp. 221-227, 2008.
26. H.-Y. Cho, F. Imani, L. Miller-DeGraff et al., "Antiviral activity ofNrf2 in amurinemodel of respiratory syncytial virus disease, " American Journal of Respiratory and Critical CareMedicine, vol. 179, no. 2, pp. 138-150, 2009.
27. C.W.Han, M. J. Kwun, K. H. Kimet al., "Ethanol extract of Alismatis Rhizoma reduces acute lung inflammation by suppressing NF-κB and activating Nrf2, " Journal of Ethnopharmacology, vol. 146, no. 1, pp. 402-410, 2013.
28. Y. C. Yang, C. K. Lii, Y. L. Wei et al., "Docosahexaenoic acid inhibition of inflammation is partially via cross-talk between Nrf2/heme oxygenase 1 and IKK/NF-κB pathways, " Journal of Nutritional Biochemistry, vol. 24, no. 1, pp. 204-212, 2013.
29. K. Permpoonputtana and P. Govitrapong, "The anti-inflammatory effect of melatonin on methamphetamine-induced proinflammatorymediators in human neuroblastoma dopamine SHSY5Y cell lines, " Neurotoxicity Research, vol. 23, no. 2, pp. 189-199, 2013.
30. R. Checker, R. S. Patwardhan, D. Sharma et al., "Schisandrin B exhibits anti-inflammatory activity through modulation of the redox-sensitive transcription factorsNrf2 andNF-kappaB, " Free Radical Biology andMedicine, vol. 53, no. 7, pp. 1421-1430, 2012.
31. A. Minelli, S. Grottelli, A. Mierla, F. Pinnen, I. Cacciatore, and I. Bellezza, "Cyclo(His-Pro) exerts anti-inflammatory effects by modulating NF-κB and Nrf2 signalling, " The International Journal of Biochemistry & Cell Biology, vol. 44, no. 3, pp. 525-535, 2012.